Related Experiment Video
Updated: Oct 21, 2025
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Topiramate For Migraine Prophylaxis Among Children Aged 5 To 15 Years
Muhammad Khalil Surani1, Muhammad Yousuf2, Naveed Anjum2
1Department of Paediatric Medicine, Children Hospital & The Institute of Child Health, Multan, Pakistan.
Insights
Topiramate (TPM) effectively reduces migraine frequency, severity, and duration in children aged 5-15. This study found TPM to be a safe and beneficial option for pediatric migraine prophylaxis.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Migraine is a prevalent neurological disorder in children.
- Limited data exists on the safety and efficacy of topiramate (TPM) for pediatric migraine prophylaxis.
Purpose of the Study:
- To evaluate the efficacy and safety of topiramate (TPM) for migraine prophylaxis in children aged 5-15 years.
Main Methods:
- 132 children (5-15 years) with migraine (ICHD-II criteria) were enrolled.
- Headache frequency, severity, and duration were assessed before and after 3 months of TPM treatment.
- TPM side effects were monitored.
Main Results:
- A good treatment response was observed in 77.3% of children (102 out of 132).
- Significant reductions in headache frequency, severity, and duration were noted (p < 0.05).
- No serious adverse events were reported during TPM treatment.
Conclusions:
- Topiramate (TPM) is an effective and safe prophylactic treatment for migraine in children.
- TPM significantly decreases headache frequency, severity, duration, and associated disability in the pediatric population.
Background:
Migraine is known to be a common neurological disorder among children. Newer anti-epileptic agents like topiramate (TPM) have shown to decrease the frequency of headache but not much work about safety and efficacy of TPM is seen in the paediatric population with migraine. This study was aimed to find out the efficacy and safety of TMP for migraine prophylaxis among children aged 5-15 years.
Methods:
A total of 132 children having migraine headache according to ICHD-II criterion for duration of at least 6 months, from 5-15 years of age were enrolled. Frequency of headache, severity of headache and duration of headache were compared before and after 3 months of TPM treatment. Side effects of TPM treatment were also observed.
Results:
In a total of 132 children, 80 (60.6%) were female and 52 (39.4%) males. Mean age was 9.52±2.5 years. Good response of TPM treatment was observed in 102 (77.3%) children. Significant decrease (p value <0.05) was noted in headache frequency, severity and duration following TPM treatment. No serious side effects of TPM treatment were noted.
Conclusions:
Topiramate is noted to be effective and safe for migraine prophylaxis among children. Reduction in headache frequency, severity as well as duration and disability scores are recorded after TPM treatment.
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists